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Abstract Neutrophil and monocyte differentiation can be
induced in HL60 leukaemia cells by all-trans-retinoic acid
(ATRA) and 1K,25-dihydroxyvitamin D3 (D3), respectively,
whose differentiating effects can be enhanced by exposure to
‘anti-inflammatory agents’ and steroids. We have provided
evidence that this potentiation is via inhibition of the activity of
an enzyme of the aldoketoreductase (AKR) family, but had failed
to identify expression of known AKRs in HL60 cells. In this
study, we have identified a previously unclassified aldoketo-
reductase family member (termed HAKR e) that is expressed in
HL60 cells. HAKR e is dramatically and transiently up-
regulated in HL60 cells within 24 h of exposure to ATRA,
further supporting the proposition that a member(s) of this family
of enzymes play(s) a role in controlling cell growth and/or
differentiation.
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1. Introduction
The human myeloid leukaemia-derived cell line HL60 has
been used extensively for studies of cell di¡erentiation. These
cells di¡erentiate towards neutrophils or monocytes in re-
sponse to all-trans-retinoic acid (ATRA) [1] and 1K,25-dihy-
droxyvitamin D3 (D3) [2], respectively. In our previous stud-
ies, we observed that sensitivity of HL60 cells to the
di¡erentiating e¡ects of these two agents is increased by the
addition of various agents. Initially, the ‘anti-in£ammatory
agents’ indomethacin and dexamethasone were observed to
potentiate ATRA-induced neutrophilic di¡erentiation and
dexamethasone was shown to potentiate D3-induced mono-
cytic di¡erentiation [3]. We investigated the possibility that
indomethacin (a cyclooxygenase inhibitor [4]) and dexametha-
sone (a phospholipase A2 inhibitor [5]) were preventing the
formation of a di¡erentiation-suppressive prostanoid. Analy-
ses of prostanoids produced by HL60 cells and attempts to
reverse indomethacin potentiation of di¡erentiation by adding
back selective prostanoids failed to identify an endogenous
prostanoid that suppresses di¡erentiation [6].
We identi¢ed other agents that potentiate HL60 di¡erentia-
tion, which are aspirin, medroxyprogesterone acetate and 17L-
estradiol [6]. These agents, together with indomethacin and
dexamethasone, are all e¡ective inhibitors of 3K-hydroxyster-
oid dehydrogenase (3K-HSD) [7^10]. We demonstrated that
medroxyprogesterone acetate and 17L-estradiol do not inter-
fere with prostanoid metabolism in HL60 cells. Furthermore,
the pharmacological pro¢le for potentiation of di¡erentiation
by all the agents we have used matches that for inhibition of
3K-HSD rather than that for inhibition of cyclooxygenase or
PLA2 [6]. A protein that is recognised by an antiserum to 3K-
HSD is expressed in HL60 cells ; this protein is the same size
(34 kDa) as rat liver 3K-HSD and as recombinant 3K-HSD.
From these studies, we concluded that decreased activity of a
so far unidenti¢ed member of the aldoketoreductase (AKR)
family of dehydrogenases leads to increased responsiveness of
HL60 cells to di¡erentiating agents [6].
3K-HSD is a member of a large family of dehydrogenases of
similar size and primary sequence. Four human enzymes have
been identi¢ed that are structurally related to 3K-HSD; these
are expressed at high levels in liver, and are known as human
aldoketoreductases a^d (HAKR a^d) [11]. We have used PCR
and restriction digest to identify which, if any, of these aldo-
ketoreductases are present within HL60 cells. From this, we
identi¢ed a further closely related member of the human
HAKR family (termed HAKR e). Analysis of levels of
mRNA and protein during HL60 neutrophil and monocyte
di¡erentiation have revealed that HAKR e expression is
ATRA inducible.
2. Materials and methods
2.1. Cell culture
Stock cultures of HL60 cells were maintained in exponential growth
in serum free conditions containing RPMI 1640 medium (Gibco, Pais-
ley, UK) containing 100 U/ml penicillin and 100 Wg/ml streptomycin
(Gibco) and supplemented with a serum replacement of 1% ITS (in-
sulin-transferrin-selenium ions) (Stratec, Luton, UK). To induce
monocyte di¡erentiation, HL60 cells were treated with a high dose
of D3. For Northern analyses of AKR mRNA levels, we used
5U1037 M D3, whilst for Western analyses of protein levels we
used 1U1037 M D3. Induction of neutrophil di¡erentiation of serum
free-grown HL60 cells requires the presence of a high dose of ATRA
(5U1037 M) together with a small amount of D3 (5U10314 M) [12].
HL60 cells were also treated with a high dose of ATRA alone
(5U1037 M), which results in growth arrest but sub-optimal neutro-
phil di¡erentiation (around 25% mature cells) [12]. For Northern
analyses, we also treated HL60 cells with a high dose of ATRA
(5U1037 M) and a moderate amount of D3 (5U1039 M), which result
in monocyte di¡erentiation [12]. Western analyses of protein levels
were undertaken up to day 5 and cultures were fed with medium
containing appropriate agents at day 2.
2.2. RT-PCR and restriction analysis of human AKR products
Cells were washed and RNA was extracted using a RNeasy kit
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(Qiagen). RNA (1 Wg) was reverse transcribed for 10 min at 42‡C, the
reverse transcriptase was inactivated at 99‡C for 15 min and ¢nally
cooled to 5‡C for 1 min. Two Wl of the RT reaction were ampli¢ed
using HAKR3P and HAKR5P primers and the following cycle con-
ditions: 5 cycles of 95‡C for 45 s, 50‡C for 60 s, 72‡C for 60 s; 30
cycles of 95‡C for 45 s, 55‡C for 60 s, 72‡C for 60 s; followed by a
soak at 4‡C. The primer sequences were: HAKR3P (antisense), 5P-
CAT TCA ACC TGG TTG CAC AC-3P ; HAKR5P (sense), 5P
GAC ATA TTC TAC ACT TCA AAG C-3P. The 346-bp fragment
ampli¢ed represented bases 239^585 of HAKR a, 242^588 of HAKR
b, 223^569 of HAKR c and 238^584 of HAKR d. PCR products were
run on a 1.5% agarose gel, and the resultant fragment size was, as
expected, around 350 bp.
PCR fragments were initially digested with BsaI, BbvI or AvaII for
comparison with the digest patterns for the four HAKRs. A second
series of enzymes (HinfI, BbvI, NcoI or BsaI) were used to re¢ne
identity. The PCR fragment was used to screen a cDNA library
from uninduced HL60 cells. Two matches were sequenced and com-
pared to the four published sequences for HAKR a^d. The clone
KIAA0119 (a novel HAKR) was a gift from Kazusa DNA Research
Institute, Kasuza, Chiba, Japan.
2.3. Analyses of HAKR mRNA and protein levels
RNA (5 Wg) from uninduced HL60 cells and from HL60 cells
treated with di¡erentiation agents for 1, 2 and 3 days were run in a
formamide agarose gel, and Northern blotted. The blot was hybrid-
ised overnight with the full length KIAA0119 clone, which is identical
in sequence to HAKR e, at 65‡C, washed and exposed for 48 h. The
¢lter was also probed with an actin cDNA to con¢rm equal loading.
The ¢lters were scanned and the expression level of HAKR e relative
to that of ABL obtained.
HAKR protein levels were measured by immunostaining Western
blots with a rabbit polyclonal antiserum raised against rat 3K-HSD.
This antiserum (71536) was a gift from Professor T. Penning, Univer-
sity of Pennsylvania. Brie£y, extracts from 5U106 cells were boiled in
sample bu¡er and loaded onto a 12.5% SDS-polyacrylamide gel. After
electrophoresis at 120 V, proteins were transferred onto an Immobi-
lon-P (Millipore) membrane, which was blocked with Tris-bu¡ered
saline Tween 20 (0.1%, pH 7.5), 2.5% milk powder for 1 h, then
incubated with the rabbit antiserum (at 1:800 in PBS). Antibodies
bound to proteins were detected using an ECL chemiluminescence
system (Amersham). Gel lanes were loaded with equal amounts of
proteins and to ensure even loading the membrane was stained after-
wards with Ponceau S. Densitometry was performed on the bands to
quantify changes in HAKR protein levels.
3. Results
3.1. HL60 cells express a novel HAKR
To identify which, if any, of the four known HAKRs is
present in HL60 cells, RNA was reverse transcribed and am-
pli¢ed by PCR using primers that £ank a region of high
homology (98%). This region, between 242 and 588 bp (in
HAKR b), was also chosen because sequence di¡erences be-
tween HAKRs can be identi¢ed by simple restriction fragment
analyses of PCR fragments (Table 1A). Restriction analysis
suggested that the PCR fragment ampli¢ed from HL60 cells
consisted of either HAKR b (288) or HAKR c (290). Further
restriction analyses, with a second series of enzymes, indicated
that the vast majority of the PCR product was or closely
resembled HAKR b (280) (Table 1B).
The HAKR PCR fragment was used to probe an uninduced
HL60 cDNA library. Two positive clones were identi¢ed. Se-
quence analysis of these clones indicated a very close homol-
ogy with HAKR b (98.5%), however, both clones had 100%
homology with a cDNA (D17793, KIAA0119) isolated from a
library constructed from the human myeloid cell line KG1
[13]. We suggest that KIAA0119 should be classi¢ed as
HAKR e. This HAKR has only a 1.1% divergence from
HAKR b, and, in the analyses undertaken, shows the same
restriction enzyme digestion pattern as HAKR b.
3.2. Expression of HAKR e is ATRA inducible
Treatment of serum free-grown HL60 cells with 5U1037 M
ATRA together with 5U10314 M D3 resulted in maximum
di¡erentiation to neutrophils. After such treatment and at
day 5, 72% of cells phagocytosed yeast and 6 0.5% of cells
were stained for monocyte speci¢c esterase (ANAE), using K-
napthyl-acetate as substrate. At day 1, there was an initial
dramatic increase in expression of mRNA followed by a grad-
ual down-regulation of the mRNA (Fig. 1). A similar pattern
of expression was observed when HL60 cells were treated with
5U1037 ATRA alone. The use of ATRA alone, as reported
FEBS 21188 30-11-98
Table 1
Restriction digest analysis of the HAKR expressed in HL60 cells
A Accession
no.
BsaI BbvI AvaII
No. of
bands
Fragment
lengths
No. of
bands
Fragment
lengths
No. of
bands
Fragment
lengths
HAKR a S68287 2 166, 181 2 46, 301 2 70, 277
HAKR b S68288 1 346 2 46, 301 3 25, 25, 297
HAKR c S68290 1 346 2 70, 277 2 50, 297
HAKR d S68330 1 346 ^ 346 2 50, 297
PCR fragment 1 V350 1+ V50, V300 1+ V300
B Accession
no.
HinfI BbvI NcoI BsaI
No. of
bands
Fragment
lengths
No. of
bands
Fragment
lengths
No. of
bands
Fragment
lengths
No. of
bands
Fragment
lengths
HAKR b S68288 2 37, 310 2 46, 301 2 130, 217 1 346
HAKR d S68330 1 346 2 70, 277 1 346 1 346
PCR fragment 1+ V310 1+ V300 2 V130, V220 1 V350
PCR fragment, approximate size 350 bp, ampli¢ed using HAKR5P and HAKR3P primers were digested initially with BsaI, BbvI and AvaII
individually (A). These digests suggested that the PCR fragment was either HAKR b or HAKR d. Further digests (B) indicated that the vast
majority of the PCR product was HAKR b. The 1+ indicates that only 1 fragment was observed by ethidium bromide staining, but was smaller
than the undigested PCR fragment, therefore the smaller digest fragments were presumable present, but undetected.
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previously [13], resulted in sub-optimal neutrophil di¡erentia-
tion (25% mature cells). HAKR e mRNA levels were unaf-
fected when HL60 cells were treated with 5U1037 M D3 to
induce monocyte di¡erentiation. Following this induction reg-
imen, and at day 5, 77% of cells were observed to phagocytose
yeast and 66% of cells expressed ANAE. An immediate up-
regulation in the level of expression of HAKR e mRNA was
observed when HL60 cells were treated with a high dose of
ATRA (5U1037 M) together with a moderate dose of D3
(5U1039 M). This combination of a high dose of ATRA
and a moderate amount of D3, as reported previously [13],
induced HL60 cells to di¡erentiate to monocytes. Levels of
mature monocytes were comparable to those observed in
cultures treated with the high dose of D3 alone. Thus, an
immediate up-regulation of HAKR e mRNA expression was
observed post-ATRA treatment per se and irrespective of
whether HL60 cells had undergone neutrophil di¡erentia-
tion or monocyte di¡erentiation or even maximum di¡eren-
tiation.
Analyses of changes in HAKR e proteins levels during
HL60 di¡erentiation were undertaken by immunostaining
blots with an antibody to 3K-HSD (Fig. 2). In these experi-
ments, analyses where extended up to day 5. At day 5, per-
centages of mature cells (phagocytic) in cultures that had dif-
ferentiated to neutrophils (5U1037 M ATRA/5U10314 D3)
and monocytes (1U1037 M D3) were 78% in both instances.
Sub-optimal neutrophil di¡erentiation was observed in cul-
tures treated with 5U1037 M ATRA alone (28% phagocytic
cells). Between days 0 to 3, data obtained for protein levels
(see Fig. 2) parallel the observations from Northern blots for
mRNA levels. During neutrophil di¡erentiation, induced by
treatment with 5U1037 M ATRA/3.9U10314 M D3, there
was an immediate up-regulation of expression of HAKR e
protein followed by a return to the level observed in unin-
duced HL60 cells. An immediate up-regulation, at day 1, was
also observed when HL60 cells were treated with 5U1037
ATRA alone. There was then a reduction in the level of pro-
tein, at day 2, followed by a further increase post-feeding the
cells, at day 2, with ATRA. HAKR e protein levels did not
change between days 0 to 3 in HL60 cells treated with
1U1037 M D3 to induce monocyte di¡erentiation. In termi-
nally di¡erentiated neutrophils (5 days post treatment with
5U1037 M ATRA/3.9U10314 M D3) and monocytes (5
days post treatment with 1U1037 M D3) levels of HAKR e
expression were lower than that observed in uninduced HL60
cells. This down-regulation of expression was not observed in
cells from cultures which had been treated with 5U1037
ATRA alone and which had showed sub-optimal neutrophil
di¡erentiation.
We examined the e¡ect of indomethacin (an inhibitor of
3K-HSD) on HAKR e expression in HL60 cells deriving a
stock of cells (serum free) that has been maintained, for s 6
months, in 20 WM indomethacin. These cells grow slower that
the parental cells (doubling time of 36 h vs. 24 h) and have
increased sensitivity to vitamin D3. Concentrations of D3 re-
quired to give 50% maturation (phagocytic cells) of indometh-
acin grown cells, cells co-treated with 20 WM indomethacin
and D3 alone were 1.4 nM, 4 nM and 42 nM, respectively
(n = 3). Repeated determinations of the levels of HAKR e in
indomethacin-grown HL60 cells vs. parental cells has shown
that indomethacin has no e¡ect on the level of expression of
HAKR e (data not shown).
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Fig. 2. Changes in HAKR e proteins levels during HL60 neutrophil
and monocyte di¡erentiation. A: A representative Western blot of
protein extracts from uninduced HL60 cells (lanes 1 and 12) and
HL60 cells undergoing growth arrest and limited neutrophil di¡eren-
tiation (5U1037 M ATRA) (lanes 2^6 represent days 1^5 of induc-
tion), neutrophil di¡erentiation (5U1037 M ATRA/5U10314 M D3)
(lanes 7^11 representing days 1^5 of induction) or monocyte di¡er-
entiation (1U1037 M D3) (lanes 13^16 represent days 1^4 of induc-
tion). B: Changes in protein levels relative to the amount present in
uninduced HL60 cells. HL60 cells were induced to undergo neutro-
phil di¡erentiation (^ F ^), monocyte di¡erentiation (^ R ^) or
growth arrest and limited neutrophil di¡erentiation (- - 8 - -), using
the above conditions.
Fig. 1. HAKR e is ATRA inducible. A: Northern blot of RNA ex-
tracted from uninduced HL60 cells (lanes 1), or cells exposed to
5U1037 M ATRA (limited neutrophil di¡erentiation) (lanes 2^4),
5U1037 M ATRA/5U1039 M D3 (monocyte) (lanes 5^7), 5U1037
M ATRA/5U10314 M D3 (neutrophil) (lanes 8^10) or 5U1037 M
D3 (monocyte) (lanes 11^13) over a 3-day period of exposure. Lanes
2, 5, 8 and 11 represent day 1, lanes 3, 6, 9 and 12 are day 2, and
lanes 4, 7, 10 and 13 are day 3. The ¢lter was hybridised with the
full length KIAA0119 cDNA. B: Relative expression of KIAA0119
on each of the days of the ATRA/D3 treatments standardised for
loading and calculated relative to expression in uninduced HL60
cells. (^ F ^) Limited neutrophil di¡erentiation (5U1037 M ATRA
only); (^ R ^) neutrophil (5U1037 M ATRA, 5U1039 M D3) ;
(- - U - -) monocyte (5U1037 M ATRA, 5U10314 M D3) ; (^ *- -)
monocyte (5U1037 M D3 only).
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4. Discussion
Proposition of the involvement of an aldoketoreductase in
the control of cell di¡erentiation arose from studies which
showed that potentiators of HL60 di¡erentiation, such as in-
domethacin, dexamethasone, aspirin, medroxyprogesterone
acetate and 17L-estradiol, are all e¡ective inhibitors of 3K-
HSD [7^10]. A 3K-HSD-like protein is expressed in HL60
cells. Four human aldoketoreductases have been identi¢ed,
with close homology to each other and to 3K-HSD [11]. The
high degree of restriction fragment length polymorphisms sug-
gested that these four proteins form the basis of a larger
family of human AKRs.
Based on the evidence presented above, we wanted to iden-
tify which, if any, of the human AKRs is expressed in HL60
cells. The PCR/restriction digest screening protocol we devel-
oped indicated that HAKR b is the major gene expressed in
HL60 cells. However, further cloning and sequencing revealed
that although the HL60 HAKR has close homology to
HAKR b, it is an additional HAKR family member. This
gene had been previously isolated from a cDNA library pro-
duced from the KG1 myeloblastic cell line [13]. The clone
(KIAA0119) was reported to have a region of homology
with another member of the AKR family of genes, chlorde-
cone reductase [13]. In addition, Lin and co-workers have
recently characterised a 3K-HSD cDNA isolated from a hu-
man prostate cDNA library (termed type 2 3K-HSD) [14].
Comparison of the sequence of clone KIAA0119 with the
nucleotide sequence of the human prostate type 2 3K-HSD
clone revealed a single base di¡erence, which does not a¡ect
the predicted amino acid sequence. Thus, the HAKRs cloned
from HL60 cells, KG1 cells and prostate cells are identical.
Interestingly, HAKR e has been cloned from KGI and
HL60 cells, which are myeloid leukaemic cells with minimal
morphological maturation. We have postulated that the en-
zyme activity suppresses di¡erentiation, which could occur as
a consequence of promotion of proliferation. In other words,
the enzyme product favours proliferation over di¡erentiation.
Lin and co-workers have studied levels of HAKR e mRNA in
primary cultures of epithelial and stromal cells derived from
normal tissues, benign prostatic hyperplasia and prostate car-
cinoma tissues [14]. Elevated mRNA levels were observed in
epithelial cells derived from benign prostatic hyperplasia and
prostate carcinoma. Characterisation of this enzyme, by Lin
and co-workers [14], has revealed bifunctional 3K/17L-HSD
activity. Hence, these investigators have postulated that in-
creased HAKR activity in diseased prostate may either inter-
fere with the e¡ects of androgens on the abnormal growth of
prostate carcinoma cells or re£ect androgen-independent
growth of the gland. In HL60 and KG1 leukaemia cells and
prostate carcinoma cells, activity of HAKR e may be ‘pro-
proliferation’ and, as such, reduce the capacity of cells to
respond to di¡erentiating agents.
Analyses of HAKR e mRNA and protein levels in HL60
cells treated with amounts of ATRA and D3, alone and in
combination, have revealed that this enzyme is ATRA induc-
ible. Immediate up-regulation of enzyme expression occurred
post-treatment with ATRA per se regardless of whether HL60
cells had undergone neutrophil di¡erentiation (high dose
ATRA/low amount of D3), monocyte di¡erentiation (high
dose of ATRA and moderate amount of D3) or growth arrest
with limited di¡erentiation (high dose of ATRA alone). In our
original study, we used a priming dose of ATRA (10 nM) and
observed a very small up-regulation of HAKRe (at day 1),
followed by down-regulation, to a level of 20^30% of that in
uninduced HL60 cells [6]. The pattern of change observed
post-ATRA treatment in the experiments presented in this
paper is very similar. The di¡erence is that we observed an
initial substantial up-regulation of the level of HAKRe, fol-
lowed by down-regulation to a level of 35% of that present in
uninduced cells. The now clearly de¢ned initial rise in HAKR
e is presumably attributable to the higher dose of ATRA (100
nM) used in the present study. Whether the initial rise, sub-
sequent lowering of levels of HAKR e or both events a¡ect
HL60 di¡erentiation is, at present, unclear. Changes in the
level of expression were not a feature of growth arrest per
se since they were not observed when HL60 cells were induced
to di¡erentiate to monocytes by a high dose of D3 alone.
Prostate carcinoma cells are also sensitive to the anti-prolifer-
ative e¡ects of ATRA, and ATRA mediated regulation of
expression of HAKR e may be important in this context.
We do not know the substrate and product of HAKR e in
HL60 cells and, therefore, it is di⁄cult to speculate why
HAKR e is ATRA responsive. The substrate is likely to be
endogenously produced and steroid-like since potentiation ex-
periments have been undertaken using HL60 cells that had
been grown long term in serum free conditions. In this regard,
immediate up-regulation of HAKR-e post ATRA-induced dif-
ferentiation would be predicted to delay di¡erentiation and
promote cell expansion (see above). Indeed, in cultures in-
duced to undergo neutrophil di¡erentiation (by 5U1037 M
ATRA and 5U10314 M D3) mature cells appear predomi-
nantly between days 3 to 5, and post the day 1 peak of
HAKR e expression. We have, also, to reexamine whether
potentiation of di¡erentiation, by indomethacin and dexa-
methasone, is via inhibition of HAKR e activity. These agents
are known to inhibit 3K-HSD activity, but we do not know
their e¡ects on activity of the novel AKR cloned from HL60.
HAKR e has now been cloned from two undi¡erentiatied
leukaemic cell lines and is highly expressed in prostate carci-
noma cells. HAKR b, which has close homology with HAKR
e, is expressed in placenta; this tissue can be classi¢ed as a
‘di¡erentiating’ tissue. HAKR e is also ATRA responsive in
HL60 cells. These ¢ndings strengthen the argument, from
studies which revealed that potentiators of HL60 di¡erentia-
tion are inhibitors of AKR activity, that a member(s) of the
AKR enzyme family may be a key component(s) of an intra-
cellular mechanism that controls the capacity of cells to grow
and/or di¡erentiate.
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